| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910139631903321 |
|
|
Titolo |
Hydrodynamics of gas-liquid reactors [[electronic resource] ] : normal operation and upset conditions / / B.J. Azzopardi ... [et al.] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, N.J., : John Wiley & Sons, 2011 |
|
|
|
|
|
|
|
ISBN |
|
1-119-97140-3 |
1-283-17767-6 |
9786613177674 |
1-119-97071-7 |
1-119-97032-6 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (348 p.) |
|
|
|
|
|
|
Classificazione |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
|
|
Soggetti |
|
Chemical reactors - Design and construction |
Chemical reactors - Fluid dynamics - Mathematical models |
Gas-liquid interfaces |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
CONTENTS; List of Figures; List of Tables; Preface; Nomenclature; 1. Introduction; PART ONE; 2. Bubble Columns; 2.1 Introduction; 2.2 Types of Bubble Columns; 2.3 Introduction of Gas; 2.3.1 Methodology of Gas Injection; 2.3.2 Bubble Formation and Size Change; 2.3.3 Bubble Movement; 2.3.4 Void Fraction Prediction; 2.3.5 Detailed Behaviour of the Flow; 2.3.6 Gas-Liquid Mass Transfer; 2.3.7 Design of Gas Introduction Arrangement; 2.3.8 Worked Example; 2.4 Disengagement of Liquid from Gas; 2.4.1 Mechanisms of Drop Formation; 2.4.2 Drop Capture; 2.4.3 Wave Plate Mist Eliminators |
2.4.4 Mesh Mist EliminatorsQuestions; References; 3. Sparged Stirred Vessels; 3.1 Introduction; 3.2 Flow Regimes; 3.3 Variations; 3.4 Spargers; 3.5 Impellers; 3.5.1 Disc Turbines; 3.5.2 Pitched Blade Turbines; 3.5.3 Hydrofoil Impellers; 3.5.4 Multiple Impellers; 3.6 Baffles; 3.7 Power Requirements; 3.7.1 Single Impellers; 3.7.2 Multiple Impellers; 3.7.3 Single-Phase Power; 3.8 Gas Fraction; 3.9 Mass |
|
|
|
|
|
|
|
|
|
|
|
Transfer; 3.9.1 Bubble Size; 3.9.2 Interfacial Area; 3.9.3 Mass Transfer; 3.10 Mixing Times; Questions; References; 4. Thin Film Reactors; 4.1 Introduction; 4.2 Falling Film Reactors |
4.2.1 Film Thickness4.2.2 Interfacial Waves; 4.2.3 Heat and Mass Transfer; 4.3 Rotating Disc Reactors; 4.3.1 Film Thickness; 4.3.2 Interfacial Waves; 4.3.3 Mass Transfer; 4.4 Two-Phase Tubular Reactors; 4.5 Monolith Reactors; 4.5.1 Micro-Channels; 4.5.2 Flow Phenomena in Micro-Channels; 4.5.3 Numerical Modelling; Questions; References; 5. Macroscale Modelling; 5.1 Introduction; 5.2 Eulerian Multiphase Flow Model; 5.2.1 Definition; 5.2.2 Transport Equations; 5.2.3 Interfacial Forces; 5.2.4 Turbulence Models; 5.2.5 Case Study - Cylindrical Bubble Column; 5.2.6 Homogenous and Mixture Modelling |
5.3 Poly-Dispersed Flows5.3.1 Methods of Moments; 5.3.2 Case Study - Hibiki's Bubble Column; 5.4 Gassed Stirred Vessels; 5.4.1 Impeller Model; 5.4.2 Multiple Reference Frame; 5.4.3 Multiple Impellers; 5.5 Summary; Questions; References; 6. Mesoscale Modelling Using the Lattice Boltzmann Method; 6.1 Introduction; 6.2 Lattice Boltzmann Method and the Advantages; 6.3 Numerical Simulation of Single-Phase Flow and Heat Transfer; 6.3.1 LBM Model; 6.3.2 Treatment for a Curved Boundary; 6.3.3 Numerical Simulation and Results; 6.4 Numerical Simulation of Two-Phase Flow |
6.4.1 Two-Phase Lattice Boltzmann Model6.4.2 Vortices Merging in a Two-Phase Spatially GrowingMixing Layer; 6.4.3 Viscous Fingering Phenomena of Immiscible Two-FluidDisplacement; 6.4.4 Bubbles/Drops Flow Behaviour; References; PART TWO; 7. Upset Conditions; 7.1 Introduction; 7.2 Active Relief Methods; 7.3 Passive Relief Methods; References; 8. Behaviour of Vessel Contents and Outflow Calculations; 8.1 Introduction; 8.1.1 Physics of Venting Processes; 8.1.2 Typical Reactions; 8.1.3 Trends and Observations; 8.1.4 Summary of Observations and Measurements of theLevel Swell Process |
8.2 Modelling of the Level Swell Process |
|
|
|
|
|
|
Sommario/riassunto |
|
"The design of chemical reactors and their safety are as critical to the success of a chemical process as the actual chemistry taking place within the reactor. This book provides a comprehensive overview of the practical aspects of multiphase reactor design and operation with an emphasis on safety and clean technology. It considers not only standard operation conditions, but also the problems of runaway reaction conditions and protection against ensuing over-pressure. Hydrodynamics of Multiphase Reactors addresses both practical and theoretical aspects of this topic. Initial chapters discuss various different types of gas/liquid reactors from a practical viewpoint, and later chapters focus on the modelling of multiphase systems and computational methods for reactor design and problem solving. The material is written by experts in their specific fields and will include chapters on the following topics: Multiphase flow, Bubble columns, Sparged stirred vessels, Macroscale modelling, Microscale modelling, Runaway conditions, Behaviour of vessel contents, Choked flow, Measurement techniques"-- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910502660103321 |
|
|
Autore |
Hays Priya <1968-> |
|
|
Titolo |
Advancing healthcare through personalized medicine / / Priya Hays |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2022] |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[2nd ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (755 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Precision medicine |
Medicina personalitzada |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface to the Second Edition -- Acknowledgments -- Contents -- 1: "Introduction: Biomedical Innovation and Policy in the Twenty-First Century" -- Liquid Biopsy -- Challenges and Incentives for Implementation -- Components of the Book -- References -- 2: "The Rise of Genomics and Personalized Medicine" -- Human Genome Project, Sequencing, and Genomic Medicine -- New Innovative Studies in NGS -- Sanger Sequencing and Comparison with NGS -- Single-Cell RNA Sequencing -- Single-Cell Epigenetic Analysis -- Application of Single-Cell Analysis in Precision Cancer Therapy -- Genomic Medicine -- Genomic Sequencing for Assessment of Disease -- Potential Challenges of Genomic Medicine -- ENCODE: Mapping the Functional Genome -- Pharmacogenetics: Pharmacogenomics -- Thiopurine-Methyltransferase (TPMT) -- CYP2D6 -- CYP2C9 -- UDP-Glucoronyltransferase -- HIV and Abacavir -- Targeted Panel Sequencing -- Genomics-Enabled Medicine for Cancer Prognosis -- The Emergence of Personalized Medicine -- Biomarker Discovery -- Tumor Mutational Burden (TMB) as a Biomarker -- Germline Considerations -- Conclusion -- References -- 3: "Patient Narratives: Personalized Medicine in the Field" -- The Population of 1 Trial: The Story of Milasen -- The Narratives of Personalized Medicine -- Social Media's Avenues for Personalized Medicine -- Social Media |
|
|
|
|
|
|
|
|
|
for Patient Engagement -- Role of Twitter in Identifying Barriers to Care Among Patients with Metastatic Breast Cancer [6] -- The Narrative of Xin Zheng: A Lung Cancer Success Story -- References -- 4: Alliances: Knowledge Infrastructures, and the Digitization of Precision Health -- Precision Medicine: Its Potential Development and Implementation -- Implications of Precision Medicine for Patient Care and Disease Treatment -- Monitoring the Personal Genome -- Macroeconomic Considerations of Precision Medicine. |
Global Alliance for Genomics and Health -- Updates to Global Alliance for Genomics and Health: GA4GH 2020 (Figs. 4.7, 4.8, 4.9, and 4.10) -- Systems Thinking and -Omics Technologies -- Data Portals and Data Analysis -- Bridging the Gap for Translational Genomic Research -- Database Efforts -- Genomics and Artificial Intelligence -- Deep Learning Methods in Precision Medicine -- Digital Precision Health: The History of Machine Learning and the Power of Big Data for Clinical Medicine -- Digital Pathology -- Conclusion -- References -- 5: "Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics" -- An Immunotherapy Case Report -- A Target Therapy Case Report -- The Basis for Targeted Therapies: Acquired Mutations and Biomarkers in Cancers -- Oncogenesis -- Implications of Tumor Heterogeneity -- Enrichment and Adaptive Strategies -- Molecular Abnormalities in Solid Tumors -- Germline Molecular Testing for Hereditary Cancer Risk -- Cell Cycle Checkpoints -- Understanding Clinical Trials in the Era of Precision Oncology: Data, Biomarkers, and Diagnostic Testing -- Analysis -- Action -- N of 1 Trial -- Tumor Subtypes -- Breast Cancer -- Incidence and Mortality -- Inherited Breast Cancer -- Targeted Therapy Options in Breast Cancer Care -- Tyrosine Kinase Inhibitor: Tucatinib -- HER2+ /HER2-Positive Breast Cancer -- Triple-Negative Breast Cancer (TNBC) and Metastatic Breast Cancer (mBC) -- Biomarker Predicting Response to PARP Inhibitors -- "Study Supports Using MRD as a Stratification Variable for Patients with TNBC" -- "Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer" -- Olaparib -- Talazoparib -- Immunotherapy and Immunotherapy Combinations -- Newer Generation Targeted Therapy Agents -- Abemaciclib -- Other Combination Agents -- Recent Immunotherapies. |
Tecentriq -- Pembrolizumab -- Avelumab -- Liquid Biopsy in Breast Cancer: A Systematic Review -- Current Breast Cancer Diagnosis Standards -- Oncotype DX -- MammaPrint -- PAM50 (Prosigna) -- Genomic Grade Index (GGI) (Ipsogen) -- Veridex Rotterdam Signature 76 Genes -- Ventana HER2 Dual ISH DNA Probe Cocktail Assay for Detection of HER2 -- RSClin TOOL: 21-Gene Recurrence Score (RS) -- HER2DX -- Signatera MRD Test -- Findings for Protein-Truncating and Missense Variants -- "Study Suggests 86-SNV Be Incorporated in Breast Cancer Risk Prediction Models" -- Conclusion -- Colorectal Cancer -- Incidence and Mortality -- Colorectal Cancer Classification Systems -- Molecular Pathology and Diagnosis of Colorectal Cancer -- "Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile" -- Inherited CRC Syndrome -- Hereditary Nonpolyposis Colorectal Carcinoma (Lynch Syndrome) -- Familial Adenomatous Polyposis -- De Novo Colorectal Cancer -- BRAF V600E -- Additional CRC Biomarkers and Mutations -- Targeted and Immunotherapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ramucirumab -- Ziv-aflibercept -- ASPECCT Trial [76] -- Immunotherapies for CRC: A Recent Development -- Immunotherapy for the Nonimmunogenic Tumors -- Liquid Biopsy -- Conclusion -- Melanoma -- Incidence and Mortality -- Targeted Therapies -- BRAF-V600E Inhibitors -- Immunotherapies for Melanoma -- Multicenter |
|
|
|
|
|
|
|
Double-Blind Phase III IMMUNED Trial -- The Phase III Double-Blind EORTC 1325/KEYNOTE-054 Trial (continued) -- Immunotherapies in Combination with Targeted Agents -- Adoptive Cell Therapy for Metastatic Melanoma -- Liquid Biopsy -- "Pretreatment ctDNA May Help Predict Outcomes With First-Line-but Not Second-Line-Immunotherapy for Patients With Melanoma" -- Management of Brain Metastases from cuM -- Conclusion -- Lung Cancer -- Incidence and Mortality. |
Targeted Therapies -- "Pyrotinib for Pretreated Patients with HER2-Mutated Advanced NSCLC" -- Erlotinib -- Gefitinib -- Afatinib -- Capmatinib -- Dacomitinib -- Summary of Erlotinib, Gefitinib, and Afatinib -- Sotorasib -- Ceritinib -- Alectinib -- Brigatinib -- Lorlatinib -- Selpercatinib -- Pralsetinib -- Newer Targeted Therapy Agents -- Osimertinib -- Tepotinib -- Use of Liquid Biopsy in the Trial -- Poziotinib -- Ramucirumab/Erlotinib -- Mobocertinib -- Capmatinib -- Brigatinib -- Adagrasib -- Immunotherapies -- Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC -- KEYNOTE-024 -- KEYNOTE-042 -- KEYNOTE-189 -- KEYNOTE-407 -- KEYNOTE Trials Adverse Events -- IMpower Trials -- IMpower 110 -- IMpower 130 -- IMpower 131 -- IMpower 150 -- Durvalumab -- Comparative Analysis of Pembrolizumab or Nivolumab in NSCLC -- The ORIENT-11 Trial Showed Sintilimab Plus Chemotherapy Improves PFS in Advanced NSCLC -- The PD-L1 Status Dilemma -- CheckMate Trials -- CheckMate 227 -- CheckMate 9LA -- Molecular Diagnosis -- Molecular Genotyping in NSCLC -- Role of Plasma-Based Molecular Genotyping in NSCLC -- Liquid Biopsy -- Case Studies of Liquid Biopsy in Lung Cancer -- Case Study 1 -- Case Study 2 -- Case Study 3 -- Case Studies 4 and 5 -- Case Study 6 -- Conclusion -- Prostate Cancer -- Incidence and Mortality -- Genomic Medicine and Sequencing -- Newer Generation Targeted Therapies -- Prostate-Specific Membrane Antigen -- PARP Inhibitors -- "Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer" -- Rucaparib -- Non-metastatic Prostate Cancer -- PROSPER -- SPARTAN -- ARAMIS -- Summary of PROSPER, SPARTAN, and ARAMIS -- Immunotherapies -- Molecular Diagnosis -- Liquid Biopsy -- Genetic Screening -- Which Men Should Be Evaluated for Prostate Cancer?. |
Key Genomic Differences Identified in the Prostate Cancer of African-American Men -- "Series of Studies Identify Genetic Risk Factors for Prostate Cancer" -- "17q22 Loss Associated With Survival in Enzalutamide-Resistant mCRPC" -- Racial Differences in Genomic Profiles of Primary and Metastatic Prostate Cancer -- "Study Finds Differences in BRCA1/2 Male Pathogenic Variant Carriers" -- Diagnostic Tests -- 4 k Score -- Prostate Health Index (PHI) -- Prostate Cancer Antigen 3 Assay (PCA3) -- SelectMDx -- ExoDx Prostate Intelliscore (EPI) -- ConfirmMDx -- Prognostic Tests -- Decipher (GC) -- Post-operative Radiation Therapy Outcomes Score -- Promark -- Prolaris -- OncotypeDx Genomic Prostate Score (GPS) -- Precision Imaging -- Conclusion -- Central Nervous System Tumors -- Incidence and Mortality -- Molecular Classification of Glioblastoma -- Diffuse Astrocytic and Oligodendroglial Tumors -- IDH-Mutated Astrocytomas -- Biomarkers and Targeted Therapies -- Tumor Immunology -- Subset of Glioblastoma Tumors Identified as Immunotherapy Candidate -- Meningiomas -- Hemangioblastomas -- Conclusion -- Hematological Malignancies -- Incidence and Mortality -- Hematologic Oncology Highlights 2019-2020 Almanac -- Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia -- Study Finds Asciminib Safer and More Effective than TKI Bosutinib in Chronic Phase CML -- "Effects |
|
|
|
|
|
|
|
|
|
|
|
of Stopping Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia: -- Focus on Molecular Response and Patient-Reported Outcomes" -- "First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" -- Clinical Trials Investigating the Efficacy and Safety of the Novel CART Therapies UCART 19 and UCART22 in R/R B-Cell ALL -- "Chemotherapy Plus Blinatumomab for Philadelphia Chromosome-Negative B-Cell ALL". |
"FDA Grants Fast Track Designation to Allogeneic CAR T-Cell Therapy for Advanced ALL". |
|
|
|
|
|
|
3. |
Record Nr. |
UNINA990008909170403321 |
|
|
Titolo |
Archivio per l'Alto Adige |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
|
|
|
|
ISSN |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Periodico |
|
|
|
|
| |